Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about the Federal Circuit denying a request for a rehearing in a case about whether “an artificial intelligence program” may be named an inventor; and
- another article about “[a] congressional push to let drug companies patent diagnostic tests and other biotech inventions” and its potential impact.
Blake Brittain wrote an article for Reuters about the Federal Circuit denying a request for a rehearing in a case about whether “an artificial intelligence program” may be named an inventor. Brittain reported that “[t]he Federal Circuit rejected Thaler’s rehearing petition . . . without comment.” Brittain predicted that Thaler “will now petition the Supreme Court to take up the case.”
Ian Lopez and Samantha Handler co-authored an article for Bloomberg Law about “[a] congressional push to let drug companies patent diagnostic tests and other biotech inventions” and its potential impact. Lopez and Handler maintained that legislation introduced by Senator Tillis earlier this year “would reshape federal patent law to overcome several controversial US Supreme Court rulings.” Lopez and Handler also reported that IP specialists say the law could provide drugmakers with “an incentive to invest in research, a move that might have facilitated an even faster response to the coronavirus crisis.”